| Literature DB >> 20333313 |
Vinod B Shidham1, George Varsegi, Krista D'Amore.
Abstract
BACKGROUND: The evaluation of serous fluids by conventional one color immunocytochemistry is complex and challenging.Entities:
Keywords: Serous effusion; dual immunostaining; immunocytochemistry; immunohistochemistry; metastasis; serous cavity; serous fluid; two-colour immunostaining
Year: 2010 PMID: 20333313 PMCID: PMC2841748 DOI: 10.4103/1742-6413.59887
Source DB: PubMed Journal: Cytojournal ISSN: 1742-6413 Impact factor: 2.091
Summary of protocol for dual color immunostaining
Deparaffinize the section with xylene Clear xylene with a graded series of ethanol Methanol: 10 dips 50% H2O2 in Methanol- 12 minutes Deionized water: 10 dips Pretreatment (see Rinse with Tris buffer (pH 7.6). First primary antibody (300 μl) (For dilutions and other details see Rinse with Tris buffer (pH 7.6). Peroxidase labeled polymer reagent (300 μl)- 30 minutes [(Envision+ System- HRP Labeled Polymer) (Dako Code K4000 and 4001)] Rinse with Tris buffer (pH 7.6). Brown chromogen (300 μl)- 7 minutes [3,3' diaminobenzidine HCL (Dako K3467)] Rinse with deionized water. 0.1 HCl (300 μl) (To wash away excess polymer)- 5 minutes Rinse with Tris buffer (pH 7.6). Second primary antibody (300 μl) (For dilutions and other details see Alkaline phosphatase labeled polymer reagent (300 μl)- 30 minutes [Envision System- AP (Dako Code K4017 and 4018)] Rinse with Tris buffer (pH 7.6). Red chromogen (300 μl)- 14 minutes [Liquid permanent red (Dako K0640)] Rinse with deionized water. Counterstain 30 seconds with light green diluted 1:5 with deionized water Rinse with deionized water. Dehydrate quickly in100% alcohol Clear quickly with 10 dips in Xylene Coverslip with permount |
Although not required and not followed in this protocol, a protein block may be added as indicated by using ‘Dako Protein Block Serum-Free Ready-to-use (Code XO909) after step #7 and before step# 8,
The final red colored product of red chromogen may be lost if left in alcohol and xylene for longer duration
Antibodies used during initial evaluation
| Vimentin (in A) | Monoclonal, clone Vim 3B4, Dako | 1:200 | Proteinase K | First in combination A | Brown [Cytoplasmic] |
| Cytokeratin 7 (in A) | Monoclonal, clone- OV-TL 12/30 Dako | 1:400 | Proteinase K | Second in combination A | Red [Cytoplasmic] |
| Calretinin (in B and C) | Monoclonal, Clone- Dak Calret 1 Dako | 1:100 | Heat induced epitope retrieval (HIER) | First in combination B and C | Brown [Nuclear (and cytoplasmic)] |
| BerEP4 (in B) | Monoclonal, Clone- BER-EP4 Dako | 1:100 | Heat induced epitope retrieval (HIER) | Second in combination B | Red [Cytoplasmic] |
| Cytokeratin 20 (in C) | Monoclonal, clone- Ks 20.8 Dako | 1:100 | Proteinase K | Second in combination C | Red [Cytoplasmic] |
HIER, Dako Cytomation (Dako, Code S1699) Target Retrieval Working Solution for 35 minutes at 99°C, followed by cooling for 20 minutes at room temperature.
Proteinase K, Ready-to-use (Dako, Code- S3020) was diluted 1:1 with Tris-HCl buffer (pH 7.6), Antibodies were diluted with Dako Antibody Diluent (Dako, Code- SO809)
Dako: Dako Denmark A/S, Produktionsvej 42, DK-2600 Glostrup, Denmark
Combination A. First vimentin (brown) followed by cytokeratin 7 (red), Combination B. First calretinin (brown) followed by BerEP4 (red), Combination C. First calretinin (brown) followed by cytokeratin 20 (red)
Figure 1Staining pattern with dual color immunostaining counterstained with hematoxylin. *The neoplastic cells are immunoreactive for CK 7 (Red) in metastatic mammary carcinoma (a×) and immunoreactive for CK 20 (Red) in metaplastaic colonic adenocarcinoma (cZ). **The example shown in Y is a metastatic adenocarcinoma with concordant immunoreactivity for CK 7 and CK 20.
Level of difficulty of interpretation with one color versus two color immunostaining
| Case no. (All case numbers were not used) | Level of difficulty | |
|---|---|---|
| 1 color | 2 color | |
| 1 | 3 | 1 |
| 2 | 4 | 1 |
| 3 | 5 | 1 |
| 4 | 3 | 1 |
| 5 | 3 | 2 |
| 7 | 1 | 1 |
| 8 | 4 | 2 |
| 10 | 5 | 1 |
| 11 | 5 | 1 |
| 12 | 3 | 1 |
| 13 | 5 | 1 |
| 14 | 1 | 1 |
| 15 | 3 | 1 |
| 16 | 3 | 1 |
| 17 | 3 | 1 |
| 18 | 5 | 1 |
| 20 | 5 | 1 |
| 21 | 4 | 2 |
| 22 | 3 | 1 |
| 23 | 3 | 1 |
| 24 | 1 | 1 |
| 25 | 3 | 1 |
| 26 | 1 | 1 |
| 27 | 3 | 1 |
| 28 | 3 | 1 |
| 30 | 1 | 1 |
| 31 | 2 | 1 |
| 32 | 1 | 1 |
| 33 | 5 | 1 |
| 34 | 5 | 1 |
| 35 | 1 | 1 |
| 36 | 1 | 1 |
| 38 | 1 | 1 |
| 39 | 5 | 1 |
| 41 | 1 | 1 |
| 42 | 2 | 1 |
| 43 | 3 | 1 |
| Range | 1 to 5 | 1 to 2 |
| Mean | 2.95 | 1.06 |
Two-tailed P value < .0001, paired t test. (1 = easy, 5 = difficult), Number 9, 19, 29, 37, 40 were not used.
Correlation of two color immunostaining results with one color immunostaining
| Breast | 13 | 13 | 13 | 100 | 13 | 7 | 54 | 0 | 0 | × |
| Gastrointestinal | 7 | 7 | 7 | 100 | 7 | 5 | 71 | 7 | 0 | 0 |
| Pancreas | 1 | 1 | 1 | 100 | 1 | 1 | 100 | 0 | 0 | × |
| Lung | 8 | 8 | 8 | 100 | 8 | 8 | 100 | 0 | 0 | × |
| Ovary | 4 | 4 | 4 | 100 | 4 | 3 | 75 | 0 | 0 | × |
| Peritoneal | 1 | 1 | 1 | 100 | 1 | 0 | 0 | 0 | 0 | × |
| Gynecologic | 3 | 3 | 3 | 100 | 3 | 2 | 67 | 0 | 0 | × |
2c = two color; 1c = one color; V = vimentin; Cal = calretinin; CK = cytokeratin.
cases in which immunostaining combination was diagnostic.
Figure 2Metastatic breast carcinoma. a, b, c, and d. Combination A: First vimentin (brown) followed by Cytokeratin 7 (red). Reactive mesothelial cells (blue arrows) are brown (vimentin) and red, (CK-7). Inflammatory cells (red arrows) are brown (vimentin). Metastatic neoplastic cells (brown arrowheads) are only red with cytokeratin 7 immunoreactivity alone, consistent with breast as primary site
Figure 3Metastatic breast carcinoma. (a) HE stained cell block section. (b) Combination A: Metastatic mammary carcinoma cells (blue arrows) with red CK 7 immunoreactivity. Inflammatory cells with brown vimentin immunoreactivity (red arrowhead) in the background. (c) Combination B: The neoplastic cells show weak BerEP4 immunoreactivity (red). (d) Combination C: They are non-immunoreactive for CK 20. ‘c’ and ‘d’ specimen did not show significant number of mesothelial cells with lack of brown nuclear immunoreactivity for calretinin in this field as in ‘b’ (red-CK-7 with brown- vimentin)
Figure 4Metastatic adenocarcinoma as single cells. (a) HE stained cell block section. (b) Combination A: Predominantly isolated metastatic neoplastic cells (brown arrowheads) with CK 7 immunoreactivity (red). A few vimentin immunoreactive (brown) inflammatory cells (red arrow) and occasional reactive mesothelial cell (blue arrow) in the background. (c) Combination B: Occasional calretinin immunoreactive (brown) mesothelial cell (blue arrow). Isolated metastatic neoplastic cells in the background (brown arrowhead) did not show red color for BerEP4 (immunoreactive with single color peroxidase method)